Results 241 to 250 of about 38,022 (310)

SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study. [PDF]

J Diabetes Res
Müller F, Bouthillier MJ, Alshaarawy O, Azhary H, Holman HT.   +4 more
europepmc   +1 more source

Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report. [PDF]

Front Endocrinol (Lausanne)
Gandecka-Pempera A, Naskręt D, Adamska A, Zozulińska-Ziółkiewicz D.   +3 more
europepmc   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1817-1825, March 2026.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report. [PDF]

Cureus
Nicolaou D, Nicolaou N, Douglas LM, Christou S.   +3 more
europepmc   +1 more source

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1915-1923, March 2026.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source

The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson's disease with diabetes co-morbidity. [PDF]

Front Neurosci
Zhang X, Du P, Bai B, Feng P, Lian X, Hölscher C, Wang Y, Xue G.   +7 more
europepmc   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1956-1971, March 2026.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system. [PDF]

Am J Prev Cardiol
Bolden DM, Richardson V, Salahuddin T, Henderson K, Hess PL, Raghavan S, Saxon DR, Ho PM, Waldo SW, Schwartz GG.   +9 more
europepmc   +1 more source

Semaglutide versus caloric restriction‐induced weight loss: insights into effects on skeletal muscle mass and function

The Journal of Physiology, EarlyView.
Harsh Shah, Julio E. Ayala
wiley   +1 more source

Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes. [PDF]

Cardiovasc Diabetol
Sørensen KK, Yazdanfard PDW, Zareini B, Pedersen-Bjergaard U, Kosjerina V, Andersen MP, Munch A, Ohlendorff JS, Schmid S, Lanzinger S, Choudhary P, Gillies C, Gharibzadeh S, Lind M, Tasselius V, Michelsen J, Gerds TA, Torp-Pedersen C.   +17 more
europepmc   +1 more source